The therapeutic landscape in advanced non–small-cell lung cancer (NSCLC) is rapidly changing. Never have so many changes of major importance occurred within so short a time. The present perspective describes this rapid evolution and resultant increasing complexity in the therapeutic decision-making process for the practicing oncologist.
- Epidermal growth factor receptor
- Targeted therapy
- Therapeutic landscape
- Tyrosine kinase inhibitor
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Cancer Research